High-dose ibuprofen linked to small increased CV risk, EMA committee confirms

A European Medicines Agency committee has confirmed that there is a small increase in the risk of cardiovascular problems such as heart attacks and stroke in patients taking high doses – 2,400mg or more – of ibuprofen, and has recommended that the labelling of products containing the anti-inflammatory drug should be updated to reflect this risk.

A European Medicines Agency committee has confirmed that there is a small increase in the risk of cardiovascular problems such as heart attacks and stroke in patients taking high doses – 2,400mg or more – of ibuprofen, and has recommended that the labelling of products containing the anti-inflammatory drug should be updated to reflect this risk.

More from Alimentary/Metabolic

Vertex Ends One Type 1 Diabetes Cell Therapy, Shifts Focus To Another

 
• By 

Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.

Novo Scores Cardio Wins But Lilly Still Tipped To Take GLP-1 Crown

 

Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.

Novo Adds Lexicon’s Novel Obesity Drug To Deal Flurry

 

The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.

Unicycive Approaches Its First Approval, But In A Competitive Space

 

The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.

More from Therapy Areas